Literature DB >> 29449421

Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes.

Caroline E Broos1, Laura L Koth2, Menno van Nimwegen1, Johannes C C M In 't Veen3, Sandra M J Paulissen4, Jan Piet van Hamburg5, Jouke T Annema6, Roxane Heller-Baan7, Alex Kleinjan1, Henk C Hoogsteden1, Marlies S Wijsenbeek1, Rudi W Hendriks1, Bernt van den Blink1,8, Mirjam Kool9,8.   

Abstract

The lung-draining mediastinal lymph nodes (MLNs) are currently widely used to diagnose sarcoidosis. We previously reported that T-helper (Th) 17.1 cells are responsible for the exaggerated interferon-γ production in sarcoidosis lungs. In this study, we aimed to investigate 1) whether Th17.1 cells are also increased in the MLNs of sarcoidosis patients and 2) whether frequencies of the Th17.1 cells at diagnosis may correlate with disease progression.MLN cells from treatment-naive pulmonary sarcoidosis patients (n=17) and healthy controls (n=22) and peripheral blood mononuclear cells (n=34) and bronchoalveolar lavage fluid (BALF) (n=36) from sarcoidosis patients were examined for CD4+ T-cell subset proportions using flow cytometry.Higher proportions of Th17.1 cells were detected in sarcoidosis MLNs than in control MLNs. Higher Th17.1 cell proportions were found in sarcoidosis BALF compared with MLNs and peripheral blood. Furthermore, BALF Th17.1 cell proportions were significantly higher in patients developing chronic disease than in patients undergoing resolution within 2 years of clinical follow-up.These data suggest that Th17.1 cell proportions in pulmonary sarcoidosis can be evaluated as a diagnostic and/or prognostic marker in clinical practice and could serve as a new therapeutic target.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 29449421     DOI: 10.1183/13993003.01124-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  23 in total

Review 1.  Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors:  Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

Review 2.  Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions.

Authors:  Mikhail Melnikov; Vladimir Rogovskii; Alexey Boykо; Mikhail Pashenkov
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-23       Impact factor: 4.147

Review 3.  Th17.1 lymphocytes: emerging players in the orchestra of immune-mediated inflammatory diseases.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Clin Rheumatol       Date:  2022-05-11       Impact factor: 3.650

Review 4.  Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.

Authors:  Amy S McKee; Shaikh M Atif; Michael T Falta; Andrew P Fontenot
Journal:  J Immunol       Date:  2022-04-15       Impact factor: 5.426

5.  Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis.

Authors:  Sang T Kim; Xerxes Pundole; Ramona Dadu; Olivier Lambotte; Manuel Ramos-Casals; Maria E Suarez-Almazor
Journal:  Immunotherapy       Date:  2021-03-01       Impact factor: 4.196

6.  PPARγ Deficiency in Carbon Nanotube-elicited Granulomatous Inflammation Promotes a Th17 Response to a Microbial Antigen.

Authors:  Victoria Sanderford; Barbara P Barna; Robert A Barrington; Anagha Malur; Arjun Mohan; Nancy Leffler; Eman Soliman; Mary Jane Thomassen
Journal:  J Nanomed Nanotechnol       Date:  2020-02-18

7.  Involvement of Dendritic Cells and Th17 Cells in Induced Tertiary Lymphoid Structures in a Chronic Beryllium Disease Mouse Model.

Authors:  Alex KleinJan; Menno van Nimwegen; Karolina Leman; Ke-Xin Wen; Louis Boon; Rudi W Hendriks
Journal:  Mediators Inflamm       Date:  2021-05-06       Impact factor: 4.711

8.  T-bet Expression in Peripheral Th17.0 Cells Is Associated With Pulmonary Function Changes in Sarcoidosis.

Authors:  Nicholas K Arger; Siddharth Machiraju; Isabel E Allen; Prescott G Woodruff; Laura L Koth
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

Review 9.  Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.

Authors:  Raisa Kraaijvanger; Montse Janssen Bonás; Adriane D M Vorselaars; Marcel Veltkamp
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

Review 10.  Environmental Risk Factors for Sarcoidosis.

Authors:  Marc A Judson
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.